This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Infectious Disease & Immunity
PEDIATRICS Vol. 112 No. 6 December 2003, pp. 1442-1446

POLICY STATEMENT

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections

Committee on Infectious Diseases and Committee on Fetus and Newborn

Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants. This statement provides revised recommendations for administering RSV prophylaxis to infants and children with congenital heart disease, for identifying infants with a history of preterm birth and chronic lung disease who are most likely to benefit from immunoprophylaxis, and for reducing the risk of RSV exposure and infection in high-risk children. On the basis of results of a recently completed clinical trial, prophylaxis with palivizumab is appropriate for infants and young children with hemodynamically significant congenital heart disease. RSV-IGIV should not be used in children with hemodynamically significant heart disease. Palivizumab is preferred for most high-risk infants and children because of ease of intramuscular administration. Monthly administration of palivizumab during the RSV season results in a 45% to 55% decrease in the rate of hospitalization attributable to RSV. Because of the large number of infants born after 32 to 35 weeks’ gestation and because of the high cost, immunoprophylaxis should be considered for this category of preterm infants only if 2 or more risk factors are present. High-risk infants should not attend child care during the RSV season when feasible, and exposure to tobacco smoke should be eliminated.

Abbreviations: RSV, respiratory syncytial virus • RSV-IGIV, Respiratory Syncytial Virus Immune Globulin Intravenous • CLD, chronic lung disease • CHD, congenital heart disease


The following policy statements have been revised:

Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV

Pediatrics 102: 1211-1216. [Full Text]

Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use
and
Pediatrics 99: 645-650. [Full Text]

Statement of retirement:

AAP Publications Retired or Reaffirmed, October 2006

Pediatrics 119: 405-405. [Full Text]



This article has been cited by other articles:


Home page
 Med Decis MakingHome page
J. S. Sampalis, J. Langley, X. Carbonell-Estrany, B. Paes, K. O'Brien, U. Allen, I. Mitchell, J. F. Aloy, C. Pedraz, and A. F. Michaliszyn
Development and Validation of a Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalization in Premature Infants Born at 33 through 35 Completed Weeks of Gestation
Med Decis Making, July 1, 2008; 28(4): 471 - 480.
[Abstract] [PDF]

Home page
 PediatricsHome page
R. Carbajal, V. Biran, R. Lenclen, R. Epaud, P. Cimerman, P. Thibault, D. Annequin, F. Gold, and B. Fauroux
EMLA Cream and Nitrous Oxide to Alleviate Pain Induced by Palivizumab (Synagis) Intramuscular Injections in Infants and Young Children
Pediatrics, June 1, 2008; 121(6): e1591 - e1598.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. A. Lorch, A. M. Millman, X. Zhang, O. Even-Shoshan, and J. H. Silber
Impact of Admission-Day Crowding on the Length of Stay of Pediatric Hospitalizations
Pediatrics, April 1, 2008; 121(4): e718 - e730.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Section on Surgery and the Committee on Fetus and
Postdischarge Follow-up of Infants With Congenital Diaphragmatic Hernia
Pediatrics, March 1, 2008; 121(3): 627 - 632.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
E. Khemani, D. B. McElhinney, L. Rhein, O. Andrade, R. V. Lacro, K. C. Thomas, and M. P. Mullen
Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant Era
Pediatrics, December 1, 2007; 120(6): 1260 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. A. Awomoyi, P. Rallabhandi, T. I. Pollin, E. Lorenz, M. B. Sztein, M. S. Boukhvalova, V. G. Hemming, J. C. G. Blanco, and S. N. Vogel
Association of TLR4 Polymorphisms with Symptomatic Respiratory Syncytial Virus Infection in High-Risk Infants and Young Children
J. Immunol., September 1, 2007; 179(5): 3171 - 3177.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S Broughton, A Roberts, G Fox, E Pollina, M Zuckerman, S Chaudhry, and A Greenough
Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants
Thorax, December 1, 2005; 60(12): 1039 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. Prais, D. Danino, T. Schonfeld, J. Amir, and for the Israeli RSV Monitoring Group
Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis: A National Survey{dagger}
Chest, October 1, 2005; 128(4): 2765 - 2771.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
N D Embleton, C Harkensee, and M C Mckean
Palivizumab for preterm infants. Is it worth it?
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2005; 90(4): F286 - f289.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
X. Zhao and W. M. Sullender
In Vivo Selection of Respiratory Syncytial Viruses Resistant to Palivizumab
J. Virol., April 1, 2005; 79(7): 3962 - 3968.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
A. Mejias, S. Chavez-Bueno, and P. J. Sanchez
Respiratory Syncytial Virus Prophylaxis
NeoReviews, January 1, 2005; 6(1): e26 - e31.
[Full Text] [PDF]

Home page
 PediatricsHome page
S. Wegner, J. J. Vann, G. Liu, P. Byrns, C. Cypra, W. Campbell, and A. Stiles
Direct Cost Analyses of Palivizumab Treatment in a Cohort of At-Risk Children: Evidence From the North Carolina Medicaid Program
Pediatrics, December 1, 2004; 114(6): 1612 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner, L. J. Anderson, and L. K. Pickering
Annual Variation in Respiratory Syncytial Virus Season and Decisions Regarding Immunoprophylaxis With Palivizumab
Pediatrics, October 1, 2004; 114(4): 1082 - 1084.
[Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner and M. B. Rennels
Unpredictable Patterns of Viral Respiratory Disease in Children
Pediatrics, June 1, 2004; 113(6): 1814 - 1816.
[Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner, S. S. Long, and Committee on Infectious Diseases, and Committee on
Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Pediatrics, December 1, 2003; 112(6): 1447 - 1452.
[Abstract] [Full Text] [PDF]